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Summary A phase 11 trial was performed to investigate the efficacy and tolerance of vinorelbine (VNB), 5-fluorouracil (5-FU), I-leucovorin
(LLV) and recombinant human granulocyte colony-stimulating factor (G-CSF) in advanced breast cancer. Between August 1994 and October
1996, 53 patients entered this trial. Thirty-seven patients were previously untreated and 16 patients had failed previous palliative
chemotherapy with (n = 12) or without anthracyclines (n = 4). Therapy consisted of VNB 40 mg m-2 diluted in 250 ml of saline infused over
30 min on days 1 and 14 and LLV 100 mg m-2 administered by intravenous bolus injection and 5-FU 400 mg m-2 diluted in 500 ml of saline
infused over 2 h, both given on days 1-5 every 4 weeks. G-CSF was administered at 5 9g kg-' day-' subcutaneously on days 6-10 during
each cycle. Treatment was continued in cases of response or stable disease until a total of six courses were completed. The overall response
rate was 59% for chemotherapeutically naive patients (95% confidence interval 42-75%), including five complete responses (CR; 13%) and
17 partial responses (PR; 46%); ten patients (27%/6) had stable disease (SD) and only five (14%) progressed (PD). Second-line chemotherapy
with this regimen resulted in 3/16 (19%) objective remissions, but nine patients had SD and four had PD. The median time to progression was
10.5 months (range 2-23) in previously untreated patients and 7.0 months (range 2-19) in those who had failed prior chemotherapy. After a
median follow-up time of 14 months, 29 patients (55%) are still alive with metastatic disease; median survival has not been reached yet. The
dose-limiting toxicity was myelosuppression: WHO grade IlIl and IV neutropenia occurred in 15 (28%) and four patients (8%), and was
complicated by septicaemia in two; grade IlIl anaemia and thrombocytopenia were noted in four (8%) and three (6%) patients respectively.
Severe (WHO grade 3) non-haematological toxicitles included stomatitis in 6% and nausea/vomiting and alopecia in 2% each. Our data
suggest that the combination of vinorelbine, 5-fluorouracil and 1-leucovorin plus G-CSF is an effective first line regimen for treatment of
advanced breast cancer. Overall toxicity was modest, with myelosuppression being the dose-limiting side-effect. Other severe adverse
reactions were uncommon.
Keywords: advanced breast cancer; chemotherapy; vinorelbine; fluorouracil; folates
Breast cancer is the most common malignancy affecting women in
the Western world. Despite adequate primary surgical treatment.
with or without post-operative radiation therapy. 25-30%7- of
patients with negative axillary lymph nodes and more than two-
thirds of those with axillary node involvement at the time ofdiag-
nosis will have recurrent and/or metastatic disease within a decade
following surgery and will subsequently die (Valagussa et al.
1978: Bonadonna et al. 1995).
Conventional combination chemotherapy has not been able to
change the natural history of advanced breast cancer, and current
treatment approaches seem to have reached their maximum effi-
cacy. Therefore. the identification of new active agents and/or
drug combinations with a superior therapeutic index remains a
principal goal of investigational efforts. Among several different
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promising new cytotoxic acgents currently undergoing clinical
evaluation in breast cancer is a semisynthetic yinca alkaloid.
vinorelbine (VNB). It is a mitotic inhibitor that has a higher thera-
peutic index and less neurotoxicity than other vinca alkaloids
related to the lower degree of damage to axonal micotubules
(Binet et al. 1990). Given as a single agent. the drug yields
response rates of 37-60% in previously untreated patients
(Cannobio et al. 1989: Garcia-Conde et al. 1992: Romero et al.
1994: Toussaint et al. 1994: Fumoleau et al. 1994: Weber et al.
1995) and of about 30% when used as second-line therapy or
salvage chemotherapy (Degardin et al. 1994: Gasparini et al.
1994). In all of these studies. treatment was well tolerated. with
neutropenia being the most frequent and dose-limiting toxicity.
Based on these results. a substantial activity for combination regi-
mens including this agent would be anticipated. and preliminary
results seem to confirm these expectations (Scheithauer et al.
1993: Spielmann et al. 1994: Fabi et al. 1995: Nole et al. 1995:
Kornek et al. 1996).
As both vinorelbine and leucovorin-modulated 5-fluorouracil (5-
FU) (Lopirinzi et al. 1989: Swain et al. 1989: Margolin et al. 1992)
are known to be effective in advanced breast cancer. and because of
their non-overlapping toxicity except for myelosuppression. which
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Table 1 Patients' charactecs PATIENTS AND METHODS
Number of patien
Entered/evaluable
Age in years
Median
Range
Performance status
WHO 0
WHO 1
WHO 2
Disease-free interval (months)
Median
Range
Menopausal status
Premenopause
Post-menopause
Qestrogen receptor status
Poliie
Negative
Unknown
Dominant disease site
Vscera
Bone
Soft tissue
Number of organ systems involved
>3
Pror therapy
Hormone therapy
Addivant
For metastatic disease
Chemotherapy
Acquvant
For metastatic disease
Anthracycdines
O0e
53
55
29-75
14
32
7
18
0-96
14
39
28
24
1
39
6
8
13
23
17
21
19
20
16
12
4
Patient section
Eligible patients for this study had histologically diagnosed breast
cancer with documented progressive, bidimensionally measurable
advanced and/or metastatic disease. All patients were required to
be aged 75 years or younger, to have a World Health Organization
(WHO) performance status ofless than 2 and an expected survival
of more than 12 weeks and to have adequate bone marrow (leuco-
cyte count of more than 4000 (1 1, absolute granulocyte count of
more than 2000 1-' and platelet count ofmore than 100 000 1 ').
renal (serum creatinine level of less than 1.5 mg dl-') and liver
functions (total bilirubin level of less than 1.5 mg dl'. trans-
aminase level less than two times the upperlimits ofnormal). Prior
radiation therapy and a maximum of one prior regimen of
palliative chemotherapy with or without hormonal therapy were
allowed. In these patients. priortherapy must have been completed
at least 4 weeks before study entry with full resolution of toxici-
ties. All patients gave informed consent according to institutional
regulations. Patients with osteoblastic bone lesions as the only site
ofdisease, patients with CNS metastases and those with a prior or
a second coexisting invasive malignancy were excluded.
Pretreabtent and follow-up evaluation
Pretreatment evaluation included a complete medical. and phys-
ical examination with measurement of all tumour-associated
lesions. Laboratory evaluation consisted of a complete blood cell
count with platelet count and leucocyte differential count an 18-
function biochemical profile and tumour marker determinations.
Imaging procedures included chest radiography, bone scan.
skeletal bone survey and computerized tomography plus ultra-
sound ofthe abdomen. Complete blood cell counts and differential
counts were performed weekly; biochemical profiles and tumour
markers were assessed before each treatment cycle. Radiographs
or scans of areas of disease were evaluated after every two treat-
ment courses.
may be alleviated by prophylactic use of a haematopoietic growth
factor such as G-CSF, the present study was initiated
Compared with previous, encouraging pilot studies ofthis drug
combination (Lopirinzi et al, 1989; Swan et al, 1989; Margolin,
1992; Scheithauer et al, 1993; Nole et al, 1995; Kornek et al,
1996), we have used full chemotherapeutic drug doses ofvinorel-
bine and 5-FU. In addition, instead ofracemic leucovorin (LV). we
have used its laevorotatory isomer (LLV), which according to
pharmacokinetic and in vitro studies has demonstrated similar
biochemical modulatory effects at half-doses (Zittoun et al, 1993)
and improves tumour tissue uptake (Schuller et al, 1996) when
compared with racemic LV. Another potential advantage of 5-
FU/LLV might be the lower incidence of leucopenia/granulo-
cytopenia noted in phase YU studies (Machoveretal, 1992; Valone
et al, 1993) and a recent controlled trial in colorectal cancer
(Scheithauer et al, 1997). The extended duration ofthe infusion of
5-FU was also based on previous clinical studies in colorectal
cancer, suggesting less frequent and severe treatment-associated
toxicity (Machover et al. 1992), for which a cost-effective 5-day
course ofG-CSF (Ribas et al. 1996) may be sufficient to maintain
dose intensity.
Treatment protocol
Therapy consisted of VNB 40 mg m-2 diluted in 250 ml of saline
infused over 30 min on days 1 and 14 and LLV 100 mg m-' admin-
istered by intravenous bolus injection and 5-FU 400 mg m-'
diluted in 500 ml of saline infused over 2 h. both given on days
1-5 every 4 weeks. G-CSF was administered at S tg kg-' day-'
subcutaneously on days 6-10 during each cycle. Treatment was
continued in patients achieving complete response (CR), partial
response (PR) or stable disease until a total of six courses were
complete. Concomitant medications routinely administered before
cytotoxic drug administration included 8 mg of ondansetron and
8 mg ofdexamethasone.
Toxicity and dosage modification guidelines
Adverse reactions were evaluated according to WHO criteria
(Miller et al, 1981). Drug doses were reduced by 25% in subse-
quent cycles if the lowest WBC (absolute granulocyte) count was
less than 1000 pl1 (500 p1-'). the lowest platelet count was less
than 50 000 p-1 or ifany severe (i.e. > WHO grade 3) non-haema-
tological toxicity was observed in the previous cycle. Vinorelbine
was to be discontinued if a patient had progressive peripheral
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neuropathy or had experienced any other severe neurotoxicity.
Treatment could be delayed for up to 2 weeks if the WBC count
was lower than 3000 jl-' and/or the platelet count lower than
75 000 ).1. Prolonged administration ofG-CSF was recommended
in the former group ofpatients. Any patient whorequired more than
2 weeks for haematological recovery was taken offthe study.
Assessment of response
A CR required the complete disappearance of all objective
evidence ofdisease on two separate measurements at least 4 weeks
apart. A PR was defined as a more than 50% reduction in the sum
ofthe products of the perpendicular diameters ofmeasurable bidi-
mensional lesions without a CR. no progression of any lesion by
more than 25% or the appearance ofany new lesion. confirmed on
two separate measurements that were 4 weeks apart. In case of
bone metastases. CR was attributed only when there was complete
disappearance of all lesions on radiograph and PR was attributed
when decrease in size and/or recalcification of lytic lesions
occurred. Decreased density of blastic lesions or improvement in
bone scan-positive. radiograph-negative disease were not taken
into account. Progressive disease (PD) was defined as the enlarge-
ment of any existing measurable lesion by more than 25% or the
development of new metastatic lesions. Stable disease (SD) was
any measurement that did not fulfil the criteria for PR or PD. The
duration of response was measured from the onset of the best
response to the date of disease progression. The duration of
survival was measured from the time of study entry until the date
of death. All tumour measurements in patients who responded
were reviewed and confirmed by at least two principal investiga-
tors. Ninety-five per cent confidence intervals were calculated as
previously described (Anderson et al. 1982).
RESULTS
Patients' characteristics
Between August 1994 and October 1996. a total of 53 patients
entered this trial. all of whom were considered exaluable for
response and toxicity assessment. The demographic data. sites of
metastatic tumour and prior therapies are listed in Table 1. The
median age was 55 years (range 29-75). and the median WHO
performance status was 1 (range 0-2). Except for 13 patients. all
had multiple metastases involving two or more organ systems with
predominant visceral, bone and soft-tissue sites in 39. six and eight
patients respectively. Nineteen patients had received hormonal
therapy for advanced disease. and palliative first-line
chemotherapy was given to 16 women. Previous chemotherapy
consisted of cyclophosphamide. methotrexate and 5-fluorouracil
(CMF) in four patients and anthracycline-containing regimens in
12 patients. A total of 256 courses were administered to the 53
patients. The median number of treatment cycles was five (range
1-6) and the median duration of follow-up at the time of this
analysis was 14 months (range 12-26).
Response to therapy
Anti-tumour responses. according to the patients' pretreatment
status. are shown in Table 2. The overall response rate was47% for
all 53 patients (95% confidence interval 33-61%). including five
CRs (9%) and 20 PRs (38%). Nineteen patients (36%) showed
Table 2 Objective response related to prior therapy
No pior chemotherapy Pretreated
(n= 37) (n=16)
Complete remission 5 (13%) -
Partial remission 17 (46%) 3 (19%o)
No change 10 (270o) 9 (56%)
Progression 5 (14%) 4 (25%)
Overall response rate 22 (59%o) 3 (19%o)
Median time to response (months) 2.0 2.2
Median response duration (months) 9.5 10.6
Median time to progression 10.5 7.0
Median survival (months) >13.0 11.0
stabilization of disease lasting more than 3 months. and in only
nine patients ( 117%) was the disease progression not influenced by
chemotherapy. The median time to response for all patients was 2
months (range 0.8-5.5). The median duration of response in all
patients was 9.5 months (range 4.0-21) and the median time to
treatment failure was 9.0 months. with a range of2-23 months.
Among the 37 chemotherapeutically naive patients with
metastatic disease. five women (13%c) achieved CR and 17 (46%)
PR. The predominant site of tumour involvement in patients who
experienced CR was visceral in three and soft tissue in two
patients: apart from one patient. all had multiple metastases.
Fifteen of 17 patients (88%) who achieved PR had multiple metas-
tases with predominant visceral (65%s ) and soft tissue (35%e)
disease. The median duration of response in previously untreated
patients was 9.5 months (range 4-21) and median time to progres-
sion was 10.5 months (range 2-23).
Among the 16 patients who had received prior palliative
chemotherapy (including 12 patients who had received anthra-
cyclines). three (19%) responded (three PR). nine had SD and
tumours progressed in four. One patient with refractory disease
who achieved PR had multiple skeletal lesions. while the other two
patients had multiple lung and liver metastases: all had failed
previous chemotherapy containing epirubicin and cyclophos-
phamide. Duration ofresponse in chemotherapeutically pretreated
patients was 6. 11.5 and 14.5 months and median time to progres-
sion was 7.0 months (range 2-19).
Toxicity
All 53 patients who received a total of 256 cycles of therapy (512
administrations of vinorelbine). were assessable for toxicity. Side-
effects associated with treatment are listed in Tables 3 and 4. The
dose-limiting toxicity was myelosuppression. Leucopenia occurred
in 40 patients (75%) and was grade 3 or4in 14 patients (26%). The
median nadir WBC count was 3600jll (range 250-38 720 i-l )
and occurred at day 9 (as a median). The time to WBC count
recovery to more than 3000 p1l' was short. i.e. 96% ofepisodes of
leucopenia resolved within 7 days. The variations in granulocyte
counts paralleled those of WBCs: the median nadir of granulocyte
counts was 1850 1 1 (range 50-21 270 p1-1. Thrombocytopenia
was rather uncommon and rarely severe: it was noted in a total of
ten patients (19%). three of whom had grade 3 (6%). There were
no episodes of bleeding The median nadir platelet count was
219000W 1 (range 37 000-637 000W-1). with no evidence of
a cumulative nature of this side-effect. Only four patients (8%)
developed grade 3 anaemia requiring packed red blood cell (RBC)
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Table 3 Highest grade of haematological toxicity experienced (n = 53)
Number of patients (%) with toxic effects according to WHO
Grade 1 Grade 2 Grade 3 Grade 4
Leucopenia 10 (19%) 16 (30%h) 11 (21%) 3 (6%)
Neutrpenia 10 (19%) 12 (23%) 15 (28%o) 4 (8%)
Thrombocytopenia 4 (8%) 3 (6%) 3 (6%) -
Anaemia 11 (21%) 10 (19%h) 4 (8%)
Table 4 Highest grade of nonhaematogical toxicity experienced (n = 53)
Number of patients (%) with toxic effects according to WHO
Grade 1 Grade 2 Grade 3 Grade 4
Nausea/vomiting 14 (26%) 13 (25%) 1 (2%o) -
Stomatitis 12 (23%) 7 (13%h) 3 (6%) -
Diarrhoea 9 (17%) 5 (9/) - -
Alopecia 6 (11%) 3 (6%) 1 (2%) -
Infection 8 (15%) 4 (8%) 1 (2%) 1 (2%0)
Phlebitis 8 (15%) 4 (8%) - -
Neurotoxicity
Peripheral 6 (11%)
Constipation 8 (15%) 5 (9%)
Anorexia 2 (4%)
transfusion. whereas mild anaemia was recorded in 21 patients
(40%). The median nadir of haemoglobin was 11.1 g dlI (range
6.0-14.5 g dl-1). Fourteen patients developed documented infection
and two ofthem required hospitalization for sepsis.
Non-haematological side-effects are listed in Table 4.
Gastrointestinal toxicity was the most frequently encountered non-
haematological side effect (53%). although symptoms were
generally mildL confined to the day of drug administration and
responsive to standard antiemetic therapy. Stomatitis was seen in
22 patients (38%) and diarrhoea in 14 patients (26%). Chemically
induced phlebitis was observed in 12 patients (23%) and six
patients (12%) developed mild peripheral neurotoxicity.
Constipation was noted in 13 patients (25%). Uncommon non-
myelosuppressive toxicities included alopecia in ten (19%) and
anorexia in two patients (4%F). There was no G-CSF-related toxi-
city recorded in our trial.
Nine patients (17%) had at least one treatment delay of 1 week
at some time during therapy and the total number of delayed
courses was 13 (5%). The reasons for delayed courses were
haematological in five. non-haematological in five and other
reasons (Port-a-Cath implantation. urological surgery. orthopaedic
surgery) in three.
Twelve patients (23%) had a 25% dose reduction of cytotoxic
drugs during treatment according to the study protocol because of
severe haematological (n = 6) or other systemic toxicities (n = 4)
or both (n = 2). Dose intensity was calculated for each patient and
for each drug. The mean given dose intensity of the combination
was 96% of the projected dose with no significant difference
between first-line (96%) and second-line patients (93.5%). The
mean dose of vinorelbine was 19.1 mg m-2 week-' (range 15.2-20
mg m2- week-1) and the mean dose of 5-FU was 478 mg mu2
week-' (range 396-500mg m-2 week-').
Survival
As of December 1996. with a median follow-up duration of 14
months (range 12-26). 24 of all 53 patients entered have died
because ofprogressive disease. except one. who expired as a conse-
quence of coincident cardiovascular disease. Twenty-nine patients
are still alive with metastatic disease. of whom 16 had received
other oncological therapy (chemotherapy ± hormonotherapy) after
subsequent PD. The median survival duration has not been reached
yet and was > 13.0 months (range 1.5-26+) forpreviously untreated
patients and 11.0 months (range 3.5-24+) in those who had received
priorfirst-line chemotherapy.
DISCUSSION
Most patients with metastatic breast cancer will receive systemic
chemotherapy at somepoint during the course oftheirdisease. In the
United States and in Europe, the standard first-line chemotherapeutic
regimen is usually either CMF (cyclophosphamide 600 mg m-2 on
days 1 and 8. methotrexate 40 mg mA ondays 1 and 8. 5-fluorouracil
600 mg m-2 on days 1 and 8) or an anthracycline-containing combi-
nation such as cyclophosphamide/doxorubicin/5-fluorouracil (FAC).
Several randomized trials show that response rates are consistently
higher for anthracycline-containing regimens than those for CMF:
however, time to disease progression and overall survival are only
minimally prolonged if at all, and the toxicity associated with the
anthracylines is substantially higher(Hayes etal. 1987). Otherpallia-
tive therapeutic strategies. including the use ofaltemating non-cross-
resistant regimens. designs based on kinetic recruitment and.
especially. administration of high doses of chemotherapy with or
without autologous bone marrow orperipheral stem cell transplanta-
tion seem encouraging (Ayash et al. 1994: Hayes et al. 1995). These
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toxic effects and warrant furtherconfirmation. as they are necessarily
associated with some degree of patient selection. For the larage
majority of patients presenting with metastatic breast cancer. a still
incurable disease. research into new agents and novel combinations
capable of achievming greater response rates with acceptable toxicity
thus remains a priority.
Based on clinical trials of vinorelbine that have established the
safetv and efficacy of this yInca alkaloid as first- and second-line
chemotherapy for the treatment of metastatic breast cancer
(Cannobio et al. 1989: Garcia-Conde et al. 1992: Degardin et al.
1994: Fumoleau et al. 1994: Gasparini et al. 1994: Romero et al.
1994: Touissant et al. 1994: Weber et al. 1995). substantial activity
for combination regimens including this agent would be antici-
pated. Among several such combination regimens that have
alreadv been investigated in patients with advanced breast cancer
(Scheithauer et al. 1993: Spielmann et al. 1994: Fabi et al. 1995:
Nole et al. 1995: Kornek et al. 1996). the combination of vinorel-
bine and doxorubicin has probably shown the most promising
activitv: there was a relatively hiah rate of cardiotoxicitv (10%7)
however. resulting in three (4%7c) treatment-associated deaths
(Spielmann et al. 1994). and a recently performed comparative
study of V.NB combined with doxorubicin vs doxorubicin alone
failed to show any therapeutic difference between the two arms
(Non's et al. 1996).
In the present study. we report the first results of front-line
chemotherapy of advanced breast cancer with a combination of
vinorelbine. 5-fluorouracil and 1-leucovorin. The rationale for this
combination was the documented activity of these agents in
advanced breast cancer. their different. potentially additive or even
synergistic mechanism of action and their non-overlapping toxi-
city profile except for myelosuppression. which might be over-
come by prophylactic use of a supportive cytokine such as G-CSF.
In an attempt to further alleviate dose-limiting neutropenia/other
systemic toxicities and thus allow administration of full drug
doses. we have also decided to use the laevorotatorv isomer of LV
(rather than racemic LV). as well as an extended administration
schedule of 5-FU (2-h infusion rather than i.v. bolus injection:
Machover et al. 1992: Valone. 1993: Scheithauer et al. 1997).
Based on our previous experience with high-dose vinorelbine
(Scheithauer et al. 1993). which was not associated with an
increased rate of neurotoxicitv. a 40 mct m- dose of the semi-
synthetic yInca alkaloid was aiven every 2 weeks.
Our results suggest an encouraging anti-tumour activity.
Twenty-two of 37 (59%7) patients with disseminated disease who
had not received previous chemotherapy achieved objective remis-
sions within a median time of only 8 weeks. It seems noteworthy
that the therapeutic effectiveness was not influenced in these
patients by the extent of disease (80%7 of responding patients had
multiple turnour sites) or predominant visceral disease (64%7 of
responses). i.e. factors that have previously been demonstrated to
be related to an adverse prognosis and poor outcome (Falkson et
al. 1991). The clinical responses achieved were durable and. after
a follow-up duration of 14 months. median survival has not been
reached vet. A lower response rate of only 19%7 was noted in our
16 patients failing previous palliative anthracycline or CMF-based
chemotherapy: these therapeutic results. in fact. seem to overlap
with those achievable with vinorelbine alone. This observation
could be related. however, to the small pretreated study subpopula-
tion. the somewhat lower dose intensity of cvrtotoxic drugs given
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to these patients when compared with first-line chemotherapy
patients andlor an accumulation ofadverse prognostic features.
Granulocytopenia was the most frequent and dose-limiting side-
effect of this regimen. although it was generallv mild to moderate.
always rapidly reversible and rarely associated with infectious
complications. Vimorelbine-associated neurological symptoms
mainlv manifested as paraesthesia. hypoaesthesia or autonomic
neuropathy causing constipation. The overall incidence was
comparable with single-agent or other combination regimens
using conventional doses of vinorelbine (Hohnecker et al. 1994).
AH other non-haematolocical toxicities were of mild to moderate
intensity and were recorded in only a minority of our patients.
In conclusion. the results of this study indicate that vinorelbine.
5-FL. LLV plus G-CSF is an effective first-line treatment for
metastatic breast cancer. Its advantage over other commonly used
cvtotoxic combinations is its excellent tolerability-. particularly the
verv low incidence ofnausea and vomiting oralopecia. Based on its
potentially favourable therapeutic index. a comparative trial with
standard combinations such as CMF or FAC (5-fluorouracil
600 mgim-' on day 1. adriamycin 60 mg m- on day 1. cyclo-
phosphamide 600 mg, m-' on day 1). includincg formal measure-
ments ofquality oflife. seems warranted. The therapeutic potential
of this combination regimen in pretreated patients. however.
warrants further investigation.
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